

To Whom it may concern

June 30, 2025

Ohara Pharmaceutical Co., Ltd.

Capital Increase by JIC Venture Growth Fund 2

Ohara Pharmaceutical Co., Ltd. (CEO: Seiji Ohara, hereinafter referred to as “the Company”) has completed a capital increase to raise funds through from JIC Venture Growth Fund 2, which is managed by JIC Venture Growth Investments Co., Ltd. (hereinafter referred to as “VGI”) Details are as follows.

1. Overview of the Capital Increase and Use of Funds

The funds raised through this third-party capital increase will be allocated to the development of pediatric cancer treatments, Parkinson's disease treatments, and other medications, as well as utilized for the acquisition and development of new pipelines. Through this capital raising, we aim to accelerate the expansion of our pipeline of new drug development centered on orphan drugs, while promoting patient-centric generic drug development. We seek to contribute to Japan's healthcare system by addressing unmet medical needs and ensuring economic sustainability.

Furthermore, by strengthening our financial foundation, we aim to enhance our risk tolerance in new drug development and further strengthen our fundraising capabilities. We will also strive to strengthen the company's foundation through the recruitment of the specialist aimed at accelerating global development and the expansion of our research and development organization.

2. Our Business Structure and Future Outlook

We will continue to pursue innovation by addressing unmet medical needs from a global perspective and providing new treatment methods and medicines, for

the benefit of patients and the healthcare professionals who support them.

We place importance on connecting the needs in the medical field with technological innovation. Focusing on areas such as pediatric cancer, blood cancer, biliary tract cancer, and neurodegenerative diseases, we will utilize our global network to develop new drugs that address high unmet medical needs, while contributing to Japanese healthcare through the stable supply of reliable generic drugs and other products.

In Japan, medical drug lag and drug loss are serious social issues, even more so than in Europe and the United States. Based on the needs of the medical field, we are expanding our pipeline of pediatric drugs and working to eliminate medical drug lag by developing orphan drugs, including those for pediatric cancer.

Another mission of our company is to provide generic drugs and original drugs that are needed by patients and medical professionals. From the patient-first perspective, we will contribute to the sustainable healthcare in Japan by stably supplying reliable drugs that meet strong medical needs.

Our company is engaged in in-house drug discovery, focusing on neurodegenerative diseases, which are becoming increasingly important in society due to the aging population. We aim to develop treatments for neurodegenerative diseases, which are considered intractable, based on a development system grounded in global clinical research.

Furthermore, we continue to grow in collaboration with local companies involved in pharmaceutical manufacturing and healthcare services in emerging countries, including Africa. By supporting programs such as UNAIDS 30, which utilizes the latest innovations in Africa, we aim to contribute to global infectious disease control.

3. About JIC Venture Growth Investments

VGI is an investment management company that aims to promote innovation and solve industrial and social issues in Japan by enhancing international competitiveness through venture growth investment activities in line with the government's industrial policy. VGI places importance on accelerating innovation through the discovery and support of innovative technologies and new businesses that drive industrial transformation.

4. Comment from Mr. Refu Nakaya of JIC Venture Growth Investments

The significance of this investment lies in its aim to address unmet medical needs of patients, including those with rare diseases, and to resolve social issues in Japan such as medical drug lag and drug loss, through the growth of the Company's global new drug business. Additionally, the investment is recognized for its significance in providing growth capital to non-listed and mid-sized companies that have not previously accessed capital markets, thereby supporting the growth of regionally based leading companies. VGI will continue to support Ohara Pharmaceutical's drug development and contribute to solving global medical issues and the sustainability of Japan's medical system by addressing unmet medical needs.

<Reference>

About Ohara Pharmaceutical Co., Ltd.

Company Name: Ohara Pharmaceutical Co., Ltd.

Location: Japan, Shiga, Koka City,

Representative: CEO Seiji Ohara

Established: November 1964

URL: <https://www.ohara-ch.co.jp/>

Business Description: A pharmaceutical company specializing in the development and manufacturing of orphan drugs (medicines for rare diseases) and generic drugs. With the mission of “Everything from the patient's perspective, for the future of healthcare, trustworthy

medicines,” we are committed to innovation, aiming to address unmet medical needs and contribute to the sustainability of Japan's healthcare system.

Contact information.

Ohara Pharmaceutical Co., Ltd.

Representatives: Iyo, Kawai

TEL: 03-6740-7701 FAX: 03-6740-7702